BB Biotech

BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and from 2000 to 2023[8] on the Italian Borsa Italiana.[9] The company invests mainly in the United States and Western Europe[10] and is managed by Bellevue Asset Management, a division of Bellevue Group[11] which accounts for approximately 40% of the Group's assets under management.[12]

BB Biotech AG
TypeAktiengesellschaft
SIX: BION[1]
FWB: BBZA[2]
Euronext: BIO.MI[3]
IndustryInvestments
Founded9 November 1993 (9 November 1993)[4]
HeadquartersSchaffhausen, Switzerland[5]
Key people
Erich Hunziker
(Chairman)[6]
ProductsInvestment in biotechnology companies
Increase CHF - 357 million
(2022)[7]
Total assetsDecreaseCHF 2.578 billion
(2022)[7]
Websitewww.bbbiotech.ch

Investment activities

As a closed-end fund, with its principal activity of specialised investments in companies operating in biotech sector,[13][14] BB Biotech is the oldest-established[12] and largest entity of its kind.[11][15]

BB Biotech's investment strategy covers a long-term time horizon and targets biotechnology firms with either already established products in the marketplace[16] or promising drug candidates in advanced development stages.[17]

Aiming exclusively at human therapeutic companies, the company rules out med-tech, diagnostics and other similar activities[12] and further concentrates on firms developing therapeutic products[13] involving cell, gene and particularly RNA-based technologies.[12]

In contrast to other biotech specialists or hedge funds, Biotech as a long-only investor, does not need to rely on financial instruments to reduce individual stock or market risk.[12]

Primary geographic focus lies on small-to-mid-cap biotech companies headquartered in Western Europe[18] or the United States market[19] as a domicile for the majority of the world’s biotechnology companies,[20] or those listed on Nasdaq.[12]

While benchmarked against the Nasdaq Biotech index (in CHF),[21][22] the company uses a bottom-up approach[17] based on the fundamental analysis.[12] Its portfolio comprises around 35 companies[14] and includes holdings in Ionis Pharmaceuticals, Moderna, Neurocrine Biosciences, Argenx, Incyte, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Arvinas, Fate Therapeutics, Agios Pharmaceuticals and Halozyme Therapeutics.[23]

Over the decade leading to 2020, it consistently met its own aim to deliver 15% of annual growth in capital[12] including a 5% dividend per year.[11]

History

BB Biotech AG mainly invests in the fields of oncology, cardiovascular diseases, metabolic diseases, infectious diseases and autoimmune diseases.[14]

Core investments

The six core investments in the BB Biotech portfolio as of June 30, 2023 included Ionis Pharmaceuticals (13.3%), Argenx (11.7%), Vertex (10.4%), Neurocrine Biosciences (8.5%), Intra-Cellular Therapies  (6.9%) and Moderna (6.2%).[24]

Company figures

Company figures are as follows:[25][26]

(figures in millions CHF) 2022 2021 2020 2019 2018 2017 2016 2015
Profit/(Loss) (356)[27] (405) 691[7][28] 677 (471) 687 (802) 653
Net asset value 2'686 3'283 3'888[28] 3'393 2'885 3'539 3'003 3'978
Market capitalization 3'058 4’274 4108[29][28] 3'670 3'235 3'576 3'053 3'463

References
  1. "BION.S - BB BIOTECH AG All Listings | Reuters". www.reuters.comundefined. Retrieved 20 October 2021.
  2. "BB Biotech AG Equity | A0NFN3 | CH0038389992 | Share Price". www.boerse-frankfurt.de. Retrieved 20 October 2021.
  3. "Bb Biotech Stocks Quotes: Company Profile - Borsa Italiana". www.borsaitaliana.it. Retrieved 20 October 2021.
  4. AG, DV Bern. "BB Biotech AG". Official Companies Register of the Canton of Schaffhausen (in German). Retrieved 20 October 2021.
  5. "BB Biotech AG. Zentraler Firmenindex". www.zefix.ch (in German). Retrieved 20 October 2021.
  6. "BB BIOTECH - About us. Board of Directors". www.bbbiotech.ch. Retrieved 20 October 2021.
  7. "BB Biotech AG, BION:SWX financials - FT.com". markets.ft.com. Retrieved 31 August 2023.
  8. "Delisting from Borsa Italiana". BB Biotech. 2023-08-21. Retrieved 2023-08-31.
  9. "BB Biotech". Borsa Italiana. Retrieved 3 June 2020.
  10. "BB Biotech AG". Bloomberg. Retrieved 8 January 2022.
  11. QuotedData by Marten & Co (11 February 2021). "BB Biotech AG. A leading biotech investor" (PDF). Retrieved 7 November 2021.
  12. "BB Biotech AG - A leading biotech investor". QuotedData. 11 February 2021. Retrieved 7 November 2021.
  13. "BB Analysis - BB Biotech AG Fund - Bloomberg Markets". www.bloomberg.com. Bloomberg. Retrieved 8 January 2022.
  14. "BB Biotech AG 0JYO-GB:London Stock Exchange". CNBC. Retrieved 2 June 2022.
  15. "BB Biotech AG Share Price | BIOEE | Morningstar". Retrieved 2 June 2022.
  16. "BB Biotech AG Bearer Shares (BBAGF)". NASDAQ, Inc. Retrieved 2 June 2022.
  17. Sarah Godfrey, Mel Jenner. "BB Biotech SW: BION". Edison Investment Research Limited. Retrieved 2 June 2022.
  18. "DGAP-News: BB BIOTECH AG: Disruptive technologies are changing an entire industry". www.finanzen.ch. 24 May 2022. Retrieved 2 June 2022.
  19. "BB Biotech AG, BION:SWX profile - FT.com". markets.ft.com. Retrieved 7 November 2021.
  20. Sarah Godfrey, Mel Jenner (1 March 2021). "BB Biotech - Looking for innovation beyond the pandemic. Review". Edison Investment Research Limited. Retrieved 2 June 2022.
  21. Kadhim Shubber (24 August 2015). "US biotech tumbles into bear market". Financial Times. Retrieved 2 June 2022.
  22. Evans, Richard (9 December 2021). "Questor: biotech has been shunned this year despite the vaccines triumph – so buy these trusts". The Telegraph. Retrieved 2 June 2022.
  23. "BB Biotech - Our holdings". www.bbbiotech.ch. BB Biotech AG. Retrieved 8 January 2022.
  24. "Portfolio". BB Biotech. Retrieved 2023-08-31.
  25. finanzen.net Retrieved 1st of January 2016.
  26. "BB Biotech - Facts & Figures". BB Biotech. 11 March 2020. Archived from the original on 2016-03-21.
  27. "Annual Report 2022". BB Biotech. Retrieved 2023-08-31.
  28. "BB BIOTECH -Facts & Figures". www.bbbiotech.ch. Retrieved 20 October 2021.
  29. "BB Biotech - Annual Report 2020". BB Biotech - Annual Report 2020. Retrieved 20 October 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.